Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin for Endometrial Thickness in Tamoxifen-Treated Breast Cancer
NCT07145827Completed
- Sponsor
- Uruk University
- Start
- Jan 2024
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of liquid metformin (Aspargo Labs) in endometrial hyperplasia (EH) (2 arms), sponsored by Uruk University. Primary endpoint: Change in endometrial thickness at 12 months. Started Jan 2024; status: completed.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
endometrial hyperplasia (EH)
Beyond the preview
Go deeper on NCT07145827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07145827.